<p>截至 2025 年 9 月，亞洲市場正在應對一個複雜的環境，受全球經濟變化和地方發展影響，中國股市在國內流動性充裕的情況下出現上漲，而日本的指數在利率預期減弱的情況下也有所上升。在這種環境下，擁有強大內部持股的公司往往能夠提供穩定性，並使管理層與股東利益保持一致，因此對尋求區域增長機會的投資者具有吸引力。</p>
<h3>亞洲高內部持股的十大成長公司</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>內部持股</strong></td>
<td><strong>收益增長</strong></td>
</tr>
<tr>
<td>浙江零跑科技 (SEHK:9863)</td>
<td>14.6%</td>
<td>57.1%</td>
</tr>
<tr>
<td>Seers Technology (KOSDAQ:A458870)</td>
<td>33.9%</td>
<td>84.6%</td>
</tr>
<tr>
<td>PharmaResearch (KOSDAQ:A214450)</td>
<td>35%</td>
<td>30.9%</td>
</tr>
<tr>
<td>Oscotec (KOSDAQ:A039200)</td>
<td>12.7%</td>
<td>104.1%</td>
</tr>
<tr>
<td>Novoray (SHSE:688300)</td>
<td>23.6%</td>
<td>30.3%</td>
</tr>
<tr>
<td>Laopu Gold (SEHK:6181)</td>
<td>35.5%</td>
<td>34%</td>
</tr>
<tr>
<td>J&amp;V Energy Technology (TWSE:6869)</td>
<td>17.5%</td>
<td>24.9%</td>
</tr>
<tr>
<td>Gold Circuit Electronics (TWSE:2368)</td>
<td>31.4%</td>
<td>35.2%</td>
</tr>
<tr>
<td>Fulin Precision (SZSE:300432)</td>
<td>11.8%</td>
<td>50.7%</td>
</tr>
<tr>
<td>Ascentage Pharma Group International (SEHK:6855)</td>
<td>12.8%</td>
<td>91.9%</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們快速增長的亞洲高內部持股公司篩選器中的 616 只股票的完整列表。</p>
<p>以下是篩選器中的一些選擇。</p>
<h2>阿里巴巴健康信息技術 (SEHK:241)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> 阿里巴巴健康信息技術有限公司在中國大陸和香港運營，專注於藥品直銷、藥品電子商務平台以及醫療和數字服務，市值為 1073.2 億港元。</p>
<p><strong>運營：</strong> 該公司通過其藥品和醫療運營的分銷和開發產生了 306 億元人民幣的收入。</p>
<p><strong>內部持股：</strong> 19.3%</p>
<p><strong>收益增長預測：</strong> 每年 20.3%。</p>
<p>阿里巴巴健康信息技術的交易價格顯著低於其估計的公允價值，預計年收益增長將超過 20%。儘管收入增長預測為每年 9.9% 較慢，但仍超過香港市場的平均水平。該公司過去的收益表現強勁，去年增長了 62.1%，但面臨着低預測股本回報率和大量一次性項目影響收益質量的挑戰。</p>
<ul>
<li>在我們的收益增長報告中更詳細地瞭解阿里巴巴健康信息技術的潛力。</li>
<li>我們的阿里巴巴健康信息技術估值報告中的分析暗示其股價相較於估計價值被高估。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f0d30b15-6b0d-4c3b-a813-701ae085f025/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f0d30b15-6b0d-4c3b-a813-701ae085f025/chart/earnings-and-revenue-growth"/></p>
<p>SEHK:241 截至 2025 年 9 月的收益和收入增長</p>
<h2>Raytron Technology Ltd (SHSE:688002)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Raytron Technology Co., Ltd. 專注於中國的無冷卻紅外成像和 MEMS 傳感器技術的研發、設計、製造和銷售，市值為 399.7 億元人民幣。</p>
<p><strong>運營：</strong> Raytron Technology Co., Ltd. 主要通過其在中國的無冷卻紅外成像和 MEMS 傳感器技術運營產生收入。</p>
<p><strong>內部持股：</strong> 25.7%</p>
<p><strong>收益增長預測：</strong> 每年 26.9%。</p>
<p>Raytron Technology Ltd. 展示了強勁的增長潛力，預計年收益增長為 26.9%，超過更廣泛的中國市場。最近的產品創新，如其先進的汽車紅外夜視系統，突顯了其對技術進步和市場擴展的承諾。儘管預測的股本回報率較低，為 15.3%，但 Raytron 的收入預計將以每年 16.1% 的速度增長，超過全國平均水平，得益於強勁的過去收益增長和在自動駕駛和安全解決方案等新興領域的戰略合作。</p>
<ul>
<li>點擊這裏訪問我們關於 Raytron Technology Ltd 的完整增長分析報告，以瞭解其動態。</li>
<li>我們的估值報告顯示 Raytron Technology Ltd 可能被高估。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/955d9b28-ce5a-4aa7-b35b-3a914196153f/chart/ownership-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/955d9b28-ce5a-4aa7-b35b-3a914196153f/chart/ownership-breakdown"/></p>
<p>SHSE:688002 截至 2025 年 9 月的持股結構</p>
<h2>豆神（北京）教育科技 (SZSE:300010)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> 豆神（北京）教育科技專注於提供教育技術解決方案，市值為 171.1 億元人民幣。</p>
<p><strong>運營：</strong> 該公司的收入部分包括信息技術服務，產生了 8.7606 億元人民幣的收入。</p>
<p><strong>內部持股：</strong> 24.1%</p>
<p><strong>收益增長預測：</strong> 每年 43%。</p>
<p>豆神（北京）教育科技展現出強勁的增長前景，預計年收益和收入分別增長 43% 和 42.8%，均超過中國市場的平均水平。截至 2025 年 6 月 30 日的半年度收益顯示，銷售額從去年 3.2639 億元大幅增長至 4.4572 億元，同時淨收入也有所改善。儘管高非現金收益影響了質量指標，但內部持股仍是其戰略方向的關鍵因素。</p>
<ul>
<li>在這份增長報告中解鎖我們對豆神（北京）教育科技股票分析的全面見解。</li>
<li>我們編制的估值報告表明豆神（北京）教育科技當前的價格可能被高估。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/7038ab7e-146e-4282-af7b-ae5545fd9fc7/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/7038ab7e-146e-4282-af7b-ae5545fd9fc7/chart/earnings-and-revenue-growth"/></p>
<p>SZSE:300010 截至 2025 年 9 月的收益和收入增長</p>
<h2>讓它發生</h2>
<ul>
<li>點擊這裏訪問我們完整的 616 家高內部持股的快速增長亞洲公司的索引。</li>
<li>準備嘗試其他投資風格嗎？這 12 家公司在 COVID 之後生存並蓬勃發展，具備應對特朗普關税的正確要素。在您的投資組合感受到貿易戰的壓力之前，瞭解原因。</li>
</ul>
<p><em>這篇文章由 Simply Wall St 撰寫，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，僅使用無偏見的方法，我們的文章並不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也不考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。該分析僅考慮內部人士直接持有的股票，不包括通過其他工具如公司和/或信託實體間接持有的股票。所有預測的收入和收益增長率均以年化（每年）增長率的形式表示，時間範圍為 1-3 年。</em></p>

零跑汽車

豆神教育

<p>截至 2025 年 9 月，亞洲市場正在經歷增長，特別是在中國和日本。擁有高內部持股的公司被視為穩定的投資選擇。值得注意的公司包括浙江零跑汽車科技、Seers Technology 和豆神（北京）教育科技，它們都顯示出顯著的盈利增長。例如，豆神預計年盈利增長 43%。然而，儘管增長潛力強勁，一些公司可能被高估。此分析強調了在當前經濟環境中，內部持股在對齊管理層與股東利益方面的重要性</p>

<p>As of September 2025, Asian markets have been navigating a complex landscape marked by global economic shifts and local developments, with Chinese stock markets showing gains amid high domestic liquidity and Japan's indices rising despite tempered interest rate expectations. In this environment, companies with strong insider ownership can often provide a sense of stability and alignment between management and shareholder interests, making them attractive options for investors seeking growth opportunities in the region.</p>
<div class="lb-trans"><p>截至 2025 年 9 月，亞洲市場正在應對一個複雜的環境，受全球經濟變化和地方發展影響，中國股市在國內流動性充裕的情況下出現上漲，而日本的指數在利率預期減弱的情況下也有所上升。在這種環境下，擁有強大內部持股的公司往往能夠提供穩定性，並使管理層與股東利益保持一致，因此對尋求區域增長機會的投資者具有吸引力。</p>
</div><h3>Top 10 Growth Companies With High Insider Ownership In Asia</h3>
<div class="lb-trans"><h3>亞洲高內部持股的十大成長公司</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Insider Ownership</strong></td>
<td><strong>Earnings Growth</strong></td>
</tr>
<tr>
<td>Zhejiang Leapmotor Technology (SEHK:9863)</td>
<td>14.6%</td>
<td>57.1%</td>
</tr>
<tr>
<td>Seers Technology (KOSDAQ:A458870)</td>
<td>33.9%</td>
<td>84.6%</td>
</tr>
<tr>
<td>PharmaResearch (KOSDAQ:A214450)</td>
<td>35%</td>
<td>30.9%</td>
</tr>
<tr>
<td>Oscotec (KOSDAQ:A039200)</td>
<td>12.7%</td>
<td>104.1%</td>
</tr>
<tr>
<td>Novoray (SHSE:688300)</td>
<td>23.6%</td>
<td>30.3%</td>
</tr>
<tr>
<td>Laopu Gold (SEHK:6181)</td>
<td>35.5%</td>
<td>34%</td>
</tr>
<tr>
<td>J&amp;V Energy Technology (TWSE:6869)</td>
<td>17.5%</td>
<td>24.9%</td>
</tr>
<tr>
<td>Gold Circuit Electronics (TWSE:2368)</td>
<td>31.4%</td>
<td>35.2%</td>
</tr>
<tr>
<td>Fulin Precision (SZSE:300432)</td>
<td>11.8%</td>
<td>50.7%</td>
</tr>
<tr>
<td>Ascentage Pharma Group International (SEHK:6855)</td>
<td>12.8%</td>
<td>91.9%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>內部持股</strong></td>
<td><strong>收益增長</strong></td>
</tr>
<tr>
<td>浙江零跑科技 (SEHK:9863)</td>
<td>14.6%</td>
<td>57.1%</td>
</tr>
<tr>
<td>Seers Technology (KOSDAQ:A458870)</td>
<td>33.9%</td>
<td>84.6%</td>
</tr>
<tr>
<td>PharmaResearch (KOSDAQ:A214450)</td>
<td>35%</td>
<td>30.9%</td>
</tr>
<tr>
<td>Oscotec (KOSDAQ:A039200)</td>
<td>12.7%</td>
<td>104.1%</td>
</tr>
<tr>
<td>Novoray (SHSE:688300)</td>
<td>23.6%</td>
<td>30.3%</td>
</tr>
<tr>
<td>Laopu Gold (SEHK:6181)</td>
<td>35.5%</td>
<td>34%</td>
</tr>
<tr>
<td>J&amp;V Energy Technology (TWSE:6869)</td>
<td>17.5%</td>
<td>24.9%</td>
</tr>
<tr>
<td>Gold Circuit Electronics (TWSE:2368)</td>
<td>31.4%</td>
<td>35.2%</td>
</tr>
<tr>
<td>Fulin Precision (SZSE:300432)</td>
<td>11.8%</td>
<td>50.7%</td>
</tr>
<tr>
<td>Ascentage Pharma Group International (SEHK:6855)</td>
<td>12.8%</td>
<td>91.9%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 616 stocks from our Fast Growing Asian Companies With High Insider Ownership screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們快速增長的亞洲高內部持股公司篩選器中的 616 只股票的完整列表。</p>
</div><p>Here's a peek at a few of the choices from the screener.</p>
<div class="lb-trans"><p>以下是篩選器中的一些選擇。</p>
</div><h2>Alibaba Health Information Technology (SEHK:241)</h2>
<div class="lb-trans"><h2>阿里巴巴健康信息技術 (SEHK:241)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Alibaba Health Information Technology Limited operates in Mainland China and Hong Kong, focusing on pharmaceutical direct sales, a pharmaceutical e-commerce platform, and healthcare and digital services, with a market cap of HK$107.32 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 阿里巴巴健康信息技術有限公司在中國大陸和香港運營，專注於藥品直銷、藥品電子商務平台以及醫療和數字服務，市值為 1073.2 億港元。</p>
</div><p><strong>Operations:</strong> The company generates revenue of CN¥30.60 billion from its distribution and development of pharmaceutical and healthcare operations.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司通過其藥品和醫療運營的分銷和開發產生了 306 億元人民幣的收入。</p>
</div><p><strong>Insider Ownership:</strong> 19.3%</p>
<div class="lb-trans"><p><strong>內部持股：</strong> 19.3%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 20.3% p.a.</p>
<div class="lb-trans"><p><strong>收益增長預測：</strong> 每年 20.3%。</p>
</div><p>Alibaba Health Information Technology trades at a significant discount to its estimated fair value and is expected to see substantial earnings growth of over 20% annually. Despite slower revenue growth projections at 9.9% per year, it surpasses the Hong Kong market average. The company has experienced strong past earnings performance, growing by 62.1% last year, but faces challenges with low forecasted return on equity and large one-off items affecting earnings quality.</p>
<div class="lb-trans"><p>阿里巴巴健康信息技術的交易價格顯著低於其估計的公允價值，預計年收益增長將超過 20%。儘管收入增長預測為每年 9.9% 較慢，但仍超過香港市場的平均水平。該公司過去的收益表現強勁，去年增長了 62.1%，但面臨着低預測股本回報率和大量一次性項目影響收益質量的挑戰。</p>
</div><ul>
<li>Take a closer look at Alibaba Health Information Technology's potential here in our earnings growth report.</li>
<li>The analysis detailed in our Alibaba Health Information Technology valuation report hints at an inflated share price compared to its estimated value.</li>
</ul>
<div class="lb-trans"><ul>
<li>在我們的收益增長報告中更詳細地瞭解阿里巴巴健康信息技術的潛力。</li>
<li>我們的阿里巴巴健康信息技術估值報告中的分析暗示其股價相較於估計價值被高估。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f0d30b15-6b0d-4c3b-a813-701ae085f025/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/f0d30b15-6b0d-4c3b-a813-701ae085f025/chart/earnings-and-revenue-growth"/></p>
<p>SEHK:241 Earnings and Revenue Growth as at Sep 2025</p>
<div class="lb-trans"><p>SEHK:241 截至 2025 年 9 月的收益和收入增長</p>
</div><h2>Raytron TechnologyLtd (SHSE:688002)</h2>
<div class="lb-trans"><h2>Raytron Technology Ltd (SHSE:688002)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Raytron Technology Co., Ltd. specializes in the R&amp;D, design, manufacturing, and sales of uncooled infrared imaging and MEMS sensor technology in China, with a market cap of CN¥39.97 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Raytron Technology Co., Ltd. 專注於中國的無冷卻紅外成像和 MEMS 傳感器技術的研發、設計、製造和銷售，市值為 399.7 億元人民幣。</p>
</div><p><strong>Operations:</strong> Raytron Technology Co., Ltd. generates revenue primarily through its uncooled infrared imaging and MEMS sensor technology operations in China.</p>
<div class="lb-trans"><p><strong>運營：</strong> Raytron Technology Co., Ltd. 主要通過其在中國的無冷卻紅外成像和 MEMS 傳感器技術運營產生收入。</p>
</div><p><strong>Insider Ownership:</strong> 25.7%</p>
<div class="lb-trans"><p><strong>內部持股：</strong> 25.7%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 26.9% p.a.</p>
<div class="lb-trans"><p><strong>收益增長預測：</strong> 每年 26.9%。</p>
</div><p>Raytron Technology Ltd. demonstrates robust growth potential with forecasted annual earnings growth of 26.9%, outpacing the broader Chinese market. Recent product innovations, such as their advanced automotive infrared night vision systems, highlight their commitment to technological advancement and market expansion. Despite a lower return on equity forecast of 15.3%, Raytron's revenue is expected to grow at 16.1% annually, surpassing the national average, supported by strong past earnings growth and strategic partnerships in emerging sectors like autonomous driving and security solutions.</p>
<div class="lb-trans"><p>Raytron Technology Ltd. 展示了強勁的增長潛力，預計年收益增長為 26.9%，超過更廣泛的中國市場。最近的產品創新，如其先進的汽車紅外夜視系統，突顯了其對技術進步和市場擴展的承諾。儘管預測的股本回報率較低，為 15.3%，但 Raytron 的收入預計將以每年 16.1% 的速度增長，超過全國平均水平，得益於強勁的過去收益增長和在自動駕駛和安全解決方案等新興領域的戰略合作。</p>
</div><ul>
<li>Click here and access our complete growth analysis report to understand the dynamics of Raytron TechnologyLtd.</li>
<li>Our valuation report here indicates Raytron TechnologyLtd may be overvalued.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏訪問我們關於 Raytron Technology Ltd 的完整增長分析報告，以瞭解其動態。</li>
<li>我們的估值報告顯示 Raytron Technology Ltd 可能被高估。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/955d9b28-ce5a-4aa7-b35b-3a914196153f/chart/ownership-breakdown" alt="" original-src="https://images.simplywall.st/company/955d9b28-ce5a-4aa7-b35b-3a914196153f/chart/ownership-breakdown"/></p>
<p>SHSE:688002 Ownership Breakdown as at Sep 2025</p>
<div class="lb-trans"><p>SHSE:688002 截至 2025 年 9 月的持股結構</p>
</div><h2>Doushen (Beijing) Education &amp; Technology (SZSE:300010)</h2>
<div class="lb-trans"><h2>豆神（北京）教育科技 (SZSE:300010)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Doushen (Beijing) Education &amp; Technology focuses on providing educational technology solutions and has a market cap of CN¥17.11 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 豆神（北京）教育科技專注於提供教育技術解決方案，市值為 171.1 億元人民幣。</p>
</div><p><strong>Operations:</strong> The company's revenue segment includes Information Technology Service, generating CN¥876.06 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司的收入部分包括信息技術服務，產生了 8.7606 億元人民幣的收入。</p>
</div><p><strong>Insider Ownership:</strong> 24.1%</p>
<div class="lb-trans"><p><strong>內部持股：</strong> 24.1%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 43% p.a.</p>
<div class="lb-trans"><p><strong>收益增長預測：</strong> 每年 43%。</p>
</div><p>Doushen (Beijing) Education &amp; Technology shows strong growth prospects with forecasted annual earnings and revenue increases of 43% and 42.8%, respectively, outpacing the Chinese market averages. Recent earnings for the half year ended June 30, 2025, indicate significant sales growth to CNY 445.72 million from CNY 326.39 million a year ago, alongside improved net income. Despite high non-cash earnings impacting quality metrics, insider ownership remains a key factor in its strategic direction.</p>
<div class="lb-trans"><p>豆神（北京）教育科技展現出強勁的增長前景，預計年收益和收入分別增長 43% 和 42.8%，均超過中國市場的平均水平。截至 2025 年 6 月 30 日的半年度收益顯示，銷售額從去年 3.2639 億元大幅增長至 4.4572 億元，同時淨收入也有所改善。儘管高非現金收益影響了質量指標，但內部持股仍是其戰略方向的關鍵因素。</p>
</div><ul>
<li>Unlock comprehensive insights into our analysis of Doushen (Beijing) Education &amp; Technology stock in this growth report.</li>
<li>The valuation report we've compiled suggests that Doushen (Beijing) Education &amp; Technology's current price could be inflated.</li>
</ul>
<div class="lb-trans"><ul>
<li>在這份增長報告中解鎖我們對豆神（北京）教育科技股票分析的全面見解。</li>
<li>我們編制的估值報告表明豆神（北京）教育科技當前的價格可能被高估。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/7038ab7e-146e-4282-af7b-ae5545fd9fc7/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/7038ab7e-146e-4282-af7b-ae5545fd9fc7/chart/earnings-and-revenue-growth"/></p>
<p>SZSE:300010 Earnings and Revenue Growth as at Sep 2025</p>
<div class="lb-trans"><p>SZSE:300010 截至 2025 年 9 月的收益和收入增長</p>
</div><h2>Make It Happen</h2>
<div class="lb-trans"><h2>讓它發生</h2>
</div><ul>
<li>Click here to access our complete index of 616 Fast Growing Asian Companies With High Insider Ownership.</li>
<li>Ready To Venture Into Other Investment Styles? These 12 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏訪問我們完整的 616 家高內部持股的快速增長亞洲公司的索引。</li>
<li>準備嘗試其他投資風格嗎？這 12 家公司在 COVID 之後生存並蓬勃發展，具備應對特朗普關税的正確要素。在您的投資組合感受到貿易戰的壓力之前，瞭解原因。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.</em></p>
<div class="lb-trans"><p><em>這篇文章由 Simply Wall St 撰寫，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，僅使用無偏見的方法，我們的文章並不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也不考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。該分析僅考慮內部人士直接持有的股票，不包括通過其他工具如公司和/或信託實體間接持有的股票。所有預測的收入和收益增長率均以年化（每年）增長率的形式表示，時間範圍為 1-3 年。</em></p>
</div>

2025 年 9 月亞洲內部持股比例高的成長型公司